Gnosis by Lesaffre unveils upgraded vitaMK7 Matrix for K2 formulations
08 Dec 2021 --- Gnosis by Lesaffre is releasing a “new generation” of vitamin K2 – vitaMK7 Matrix – and an upgraded version of its previous vitaMK7 product.
The new product has enhanced stability protection of menaquinone ingredients (vitamin K2) in complex formulations with no coating, additives or additional ingredients.
“Stability is a constant issue facing commercial partners with the desire to create complex vitamin K2 formulations. Historically our R&D team has been able to guide them through the process to ensure their products were stable,” says Sophie Legrain-Raspaud, global research and applications director at Gnosis by Lesaffre.
“With vitaMK7 Matrix, that process is now more efficient because the matrix carrier embeds the K2 as MK-7 particles in the product, thus leading to products hitting the market much faster.”
Addressing formulation challenges
The company adds that the latest innovation results from a proprietary technology that protects the particles of MK-7.
“Enhancing the protection of the MK-7 molecule is an important element for those seeking to explore complex formulations that will impact health. Our team has worked extensively to ensure that our innovation would have an impact on those with a vision for what the market needs,” adds Xavier Berger, global market manager at Gnosis by Lesaffre.
VitaMK7 Matrix has enhanced protection to ensure the stability of menaquinone ingredients in complex finished product formulations.
Research shows that moisture and mineral salts are critical variables for degradation, driving the need for a protective technology to shelter the menaquinone molecules during shelf life.
A report by Kappa Bioscience in 2019 found that less than one in five vitamin K2 supplements met label claims.
Considering this, vitaMK7 Matrix addresses these formulation challenges, providing a less cumbersome and more predictable formulation process for complex K2 products. In addition, vitaMK7 Matrix offers improved uniformity of the powder, making it easier to handle and formulate.
Its “best in class” stability is particularly suitable for mineral complexes. Lastly, the vitaMK7 enables formulas to keep a short and unchanged list of ingredients with no additives.
Gnosis by Lesaffre’s previous moves
Gnosis by Lesaffre has had a productive year. Lesaffre launched a US$75 million bid to acquire outstanding shares of vitamin K2 supplier NattoPharama and completed the acquisition in May.
Also, the company gave insight into the differences between folate, folic acid and their additional forms to tackle consumer misunderstanding.
Early this year, its product S-adenosyl-L-methionine (SAMe) was found to improve pain, fatigue, depression and cognition in patients with mild traumatic brain injury.
Edited by Nicole Kerr
